| Mr Jonathan Symonds
| Mr Jonathan Symonds is Board Member at HSBC Holdings PLC. Mr Jonathan Symonds, CBE, was appointed as an independent non-executive Director of HSBC Holdings plc in April 2014. He has extensive international financial and governance experience.Mr Symonds is Chairman of HSBC Bank plc, HSBC’s European subsidiary, which offers services to clients in the UK and Continental Europe. Mr Symonds was Chief Financial Officer of Novartis AG from 2009 to 2013. Before joining Novartis he was a Partner and Managing Director of Goldman Sachs (2007-2009); Chief Financial Officer of AstraZeneca plc (1997-2007); and a Partner at KPMG (1992-1997). His governance experience includes roles as non-executive Director and chair of the audit committees of Diageo plc and QinetiQ plc. Jonathan Symonds has been Chief Financial Officer (CFO) of Novartis since 2010. He is a member of the Executive Committee of Novartis. Before joining Novartis in 2009, Mr. Symonds was partner and managing director of Goldman Sachs Group Inc. in the United Kingdom. He also has eight years of experience as CFO of AstraZeneca PLC, and previously held positions as Group Finance Director at Zeneca and partner at KPMG. From 2004 to 2007, Mr. Symonds was a director of Diageo PLC and chairman of the audit committee. Other previous roles include director and audit committee chairman of Qinetiq PLC, chairman of the 100 Group of Finance Directors, joint chairman of the Business Tax Forum, board member of the Accounting Standards Board, and founder of the Oxford University Centre for Business Taxation Research, all in the United Kingdom. Mr. Symonds graduated with a first class degree in business finance from the University of Hertfordshire, United Kingdom, in 1980, and became a Fellow of Chartered Accountants in 1982. He is a Commander of the British Empire (CBE). |
| Ms Safra Catz
| Ms Safra Catz is Board Member at HSBC Holdings PLC. Ms Safra Catz was appointed to the Board in 2008. She has a background in international business leadership, having helped transform Oracle into the largest producer of business management software and the world's leading supplier of software for information management.Ms Catz was appointed joint Chief Executive Officer of Oracle Corporation in September 2014, having previously been President and Chief Financial Officer. She joined Oracle in 1999 and was appointed to the board of directors in 2001. She was formerly Managing Director of Donaldson, Lufkin & Jenrette.S A Catz, Appointed to the Board: 2008 Current appointments include: President and Chief Financial Officer of Oracle Corporation. Joined Oracle in 1999 and appointed to the board of directors in 2001. Former appointments include: Managing Director of Donaldson, Lufkin & Jenrette. |
| Mr Sam William Laidlaw
| Mr Sam William Laidlaw is Board Member at HSBC Holdings PLC. Mr Sam Laidlaw was appointed to the Board in 2008. He has significant international experience, particularly in the energy sector, having had responsibility for businesses in four continents.Mr Laidlaw was Chief Executive Officer of Centrica plc and the lead non-executive board member of the UK Department for Transport until 31 December 2014. His other previous roles include Executive Vice President of Chevron Corporation; non-executive director of Hanson PLC; Chief Executive Officer of Enterprise Oil plc; and President and Chief Operating Officer of Amerada Hess Corporation. He was also a member of the UK Prime Minister’s Business Advisory Group.W S H Laidlaw, Appointed to the Board: 2008 Current appointments include: Chief Executive Officer of Centrica plc; and Lead Non-executive Board Member of the UK Department for Transport. Former appointments include: Executive Vice President of Chevron Corporation; non-executive director of Hanson PLC; Chief Executive Officer of Enterprise Oil plc; and President and Chief Operating Officer of Amerada Hess Corporation. Ceased to be a member of the UK Prime Minister's Business Advisory Group on 31 December 2012. |
| Mr John Lipsky
| Mr John Lipsky is Board Member at HSBC Holdings PLC. Mr John Lipsky was appointed to the Board in March 2012. He served at the International Monetary Fund as First Deputy Managing Director, Acting Managing Director from May 2011, and as Special Adviser from September 2011, until retirement in November 2011.He is currently Senior Fellow, Foreign Policy Institute at the Paul H. Nitze School of Advanced International Studies, Johns Hopkins University; a co-chairman of the Aspen Institute Program on the World Economy; a director of the National Bureau of Economic Research and the Center for Global Development; and a member of the advisory board of the Stanford Institute for Economic Policy Research and the Council on Foreign Relations. He is also Chairman of the World Economic Forum’s Global Agenda Council on the International Monetary System.J P Lipsky, Appointed to the Board: 1 March 2012 Current appointments include: Distinguished Visiting Scholar, International Economics Program at the Paul H. Nitze School of Advanced International Studies, Johns Hopkins University. Co-chairman of the Aspen Institute Program on the World Economy; director of the National Bureau of Economic Research; and member of the advisory board of the Stanford Institute for Economic Policy Research and the Council on Foreign Relations. A director of the Center for Global Development since 1 May 2012; and Global Policy Advisor for Anderson Global Macro, LLC since 4 February 2013. Former appointments include: Vice Chairman J P Morgan Investment Bank; director of the American Council on Germany and the Japan Society; and a trustee of the Economic Club of New York. |
| Mr Marc Moses
| Mr Marc Moses is Board Member at HSBC Holdings PLC. Mr Marc Moses was appointed as an Executive Director of HSBC Holdings plc in January 2014. He is Group Chief Risk Officer, with responsibility for risk and compliance, and a member of the Group Management Board, positions he has held since December 2010.Mr Moses joined HSBC in November 2005 as Chief Financial and Risk Officer with global responsibility for leading and managing the Global Banking and Markets finance and risk functions. In January 2008 he was also appointed Chief of Staff, responsible for all infrastructure in Global Banking and Markets.Mr Moses began his career at Sedgwick before joining Bankers Trust as a fixed income, money market and futures trader. He is a qualified accountant and was audit partner and head of the market risk advisory group at PricewaterhouseCoopers. In 1999 he joined JP Morgan as European chief financial officer and global head of the valuation control group.M M Moses, Joined HSBC in 2005. A Group Managing Director since 2010. Director of HSBC Insurance (Bermuda) Limited. A director of HSBC Private Bank (Suisse) SA and HSBC Private Banking Holdings (Suisse) SA since 19 September 2012. Former HSBC appointments include Chief Financial and Risk Officer, Global Banking and Markets. |
| Ms لورا تشا شيه مي لونج
| -- |
| Mr Iain Mackay
| Mr Iain Mackay is Board Member at HSBC Holdings PLC. Mr Iain Mackay was appointed as Group Finance Director of HSBC Holdings plc in December 2010. A chartered accountant, Mr Mackay joined HSBC in July 2007. From September 2009 until his appointment to the Board as Group Finance Director, Mr Mackay was Chief Financial Officer, Asia-Pacific, of HSBC Holdings plc.Before joining HSBC, Mr Mackay worked at General Electric in the US from 1996 to 2007. He joined GE as Controller of the Global Consumer Finance unit, which specialised in providing credit cards and personal loans. He then became Chief Financial Officer of GE Consumer Finance – Americas, then Chief Financial Officer of GE Healthcare – Global Diagnostic Imaging.I J Mackay, 51, Appointed to the Board: 2010, Current appointments include: member of the Group Management Board. Former appointments include: director of Hang Seng Bank Limited; Chief Financial Officer, Asia-Pacific; and Chief Financial Officer, HSBC North America Holdings Inc; Vice President and Chief Financial Officer of GE Consumer Finance and Vice President and Chief Financial Officer of GE Healthcare - Global Diagnostic Imaging. |
| Mr Douglas Flint
| Mr Douglas Flint is Chairman of HSBC Holdings PLC. Mr Flint was appointed Chairman of the Institute of International Finance in June 2012. He is a member of both the Mayor of Beijing’s and the Mayor of Shanghai’s International Business Leaders’ Advisory Councils, as well as a member of the International Advisory Board of the China Europe International Business School, Shanghai. He was an independent external member of the Financial Services Trade and Investment Board in the UK until July 2015 and has been, by invitation from the Prime Minister, a British Business Ambassador since January 2014.Mr Flint specialised in banking, multinational financial reporting, treasury and securities trading operations, group re-organisations and litigation support while at KPMG. He joined HSBC on 30 September 1995 and was appointed to the Board as Group Finance Director on 1 December 1995. In February 2010, Mr Flint’s responsibilities were broadened to that of Chief Financial Officer, Executive Director Risk and Regulation. He was appointed Group Chairman of HSBC Holdings plc on 3 December 2010. D J Flint, CBE, Appointed to the Board: 1995, Current appointments include: director of The Hong Kong Association; and Chairman of the Institute of International Finance since 6 June 2012. A member of the Mayor of Beijing's International Business Leaders' Advisory Council as well as the Mayor of Shanghai's International Business Leaders' Advisory Council; and a member of the International Advisory Board of the China Europe International Business School, Shanghai. |
| Ms Rona Fairhead
| Ms Rona Fairhead is Board Member at HSBC Holdings PLC. R A Fairhead, Appointed to the Board: 2004 Current appointments include: Chairman and director of Financial Times Group Limited; director of Pearson plc and non-executive director of The Economist Newspaper Limited. Will retire from these appointments on 27 April 2013. Non-executive member of the board of the UK Government's Cabinet Office. Former appointments include: Executive Vice President, Strategy and Group Control of Imperial Chemical Industries plc; Finance Director of Pearson plc; and Chairman and director of Interactive Data Corporation. She is an Independent Director at PepsiCo Inc since 2014. |
| Mr Simon Robertson
| Mr Simon Robertson is Deputy Chairman of HSBC Holdings PLC. Mr Simon joined the Board in 2006. His extensive international experience includes working in France, Germany, the UK and the USA.Simon Robertson has a background in international corporate advisory work with a wealth of experience in mergers and acquisitions, merchant banking, investment banking and financial markets.He is the founding member of Simon Robertson Associates LLP; a non-executive director of Berry Bros & Rudd Limited, The Economist Newspaper Limited and Troy Asset Management; a member of the International Advisory Board of Brown Advisory Limited; a Director of Immodulon Therapeutics Limited; and a trustee of the Royal Opera House Endowment Fund.Simon Robertson, Appointed to the Board: 2006 Current appointments include: non-executive Chairman of Rolls-Royce Holdings plc until 2 May 2013. The founding member of Robertson Robey Associates LLP, formerly Simon Robertson Associates LLP; non-executive director of Berry Bros. & Rudd Limited, The Economist Newspaper Limited; and, since 8 May 2012, Troy Asset Management; partner of NewShore Partners LLP; and trustee of the Eden Project Trust and the Royal Opera House Endowment Fund. Former appointments include: Managing Director of Goldman Sachs International and Chairman of Dresdner Kleinwort Benson. Ceased to be a nonexecutive director of Royal Opera House, Covent Garden Limited on 31 July 2012. |
| Mr لورد ديفيس
| -- |
| Mr فيليب سكوت
| -- |
| Mr Phil Thomson
| Mr PhilThomson is the Contact person at GlaxoSmithKline PLC, Phil was appointed Senior Vice President, Global Communications in August 2010, Senior Vice President at GlaxoSmithKline PLC - United States in January 2010, Global Communications. He has responsibility for Media Relations, Investor Relations, Corporate Responsibility, Global Community Partnerships, and Internal, Product, and Business Communications. Phil joined Glaxo Wellcome as a commercial trainee in 1996. |
| Ms Stacey Cartwright
| Ms Stacey Cartwright is Board Member at GlaxoSmithKline PLC. Ms. Stacey Cartwright Appointed on 1 April 2011. Stacey joined Burberry Group plc as Chief Financial Officer in 2003 and was appointed Executive Vice President, Chief Financial Officer in June 2008. Previously she held the role of Chief Financial Officer at Egg plc between 1999 and 2003, and from 1988 to 1999 she worked in various finance-related positions at Granada Group plc.Stacey is Chief Executive Officer of the Harvey Nichols Group of Companies. She served as Executive Vice President, Chief Financial Officer of Burberry Group plc until July 2013. Previously she held the role of Chief Financial Officer at Egg plc between 1999 and 2003, and from 1988 to 1999 she worked in various finance-related positions at Granada Group plc. In accordance with the UK Corporate Governance Code, the Board has determined that Stacey has recent and relevant financial experience. The Board has also agreed that she has the appropriate qualifications and background to be an audit committee financial expert as defined by the US Sarbanes-Oxley Act of 2002 |
| Mr Simon Dingemans
| Mr Simon Dingemans is Board Member at GlaxoSmithKline PLC. Mr Dingemans owns 0.0003% in GlaxoSmithKline PLC since February 2015. Mr. Simon Dingemans became Chief Financial Officer in April 2011 after joining as Chief Financial Officer Designate in January 2011. He is a member of the Board and the Corporate Executive Team.Simon joined GSK from Goldman Sachs International where he was a Managing Director and Partner. He joined Goldman Sachs in 1995, becoming Head of UK Investment Banking and later becoming a leader of the European Mergers and Acquisitions business. As part of his role at GSK, Simon is responsible for Global Finance and Core Business Services comprising a number of the company’s key global functions including Finance and Real Estate. He worked with GSK for over a decade prior to joining the company and was closely involved in a number of GSK’s most important strategic projects during that time, including the establishment of ViiV Healthcare. After receiving a Masters degree in Geography from Oxford University in 1985, Simon joined S.G. Warburg Group, the investment banking firm which specialised in mergers and acquisitions, becoming one of its youngest directors in 1994. Simon is a member of the Corporate Development Council for the National Theatre and Chairman of the 100 Group. |
| Mr Roy Anderson
| Mr Roy Anderson is Board Member at GlaxoSmithKline PLC. Mr. Roy Anderson Appointed on 1 October 2007. Sir Roy is Professor of Infectious Disease Epidemiology in the Faculty of Medicine, Imperial College, London. He is a member of the International Advisory Board of Hakluyt & Co Ltd, a Trustee of the Natural History Museum, London, a fellow (and member of the Science Policy Advisory Group) of the Royal Society and a fellow of the Academy of Medical Sciences and the Royal Statistical Society. Sir Roy is a member of the International Advisory Board of the HIV Monitoring Foundation, an Honorary Fellow of the Institute of Actuaries and a Foreign Associate Member of the Institute of Medicine at the US National Academy of Sciences and the French Academy of Sciences. His former positions include Rector of Imperial College and Chief Scientific Adviser at the Ministry of Defence in the UK. |
| Mr Andrew Witty
| Mr Andrew Witty is CEO in GlaxoSmithKline PLC. Mr Witty owns 0.0016% in GlaxoSmithKline PLC since February 2015. Mr. Andrew Witty became Chief Executive Officer of GlaxoSmithKline plc on 21 May 2008. He is a member of the Board and Corporate Executive Team. Andrew joined GSK in 1985. He has worked in the UK, South Africa, the USA and Singapore in various senior roles. In 2003, he was appointed President of GSK Europe and joined GSK’s Corporate Executive Team. In 2003 he was awarded the Public Service Medal by the Government of Singapore and in August 2012 was also awarded the Public Service Star. In the 2012 New Year Honours list, he was awarded a Knighthood for services to the economy and to the UK pharmaceutical industry. Andrew served as the Lead Non-Executive Board Member for the Department for Business, Innovation and Skills to December 2013. He was also President of the European Federation of Pharmaceutical Industries and Associations until June 2013. Andrew is a Member of the UK Prime Minister’s Business Advisory Group and Member of the Global Health Innovation Advisory Board, Imperial College London. He is Chancellor of the University of Nottingham and was appointed to the UK Business Ambassador Group in January 2014. Andrew has a Joint Honours BA in Economics from the University of Nottingham. |
| Mr Tom De Swaan
| Mr Tom De Swaan was Board Member at GlaxoSmithKline PLC between 01 January 2006 and 07 May 2015. Mr. Tom De Swaan Appointed on 1 January 2006. Tom is Chairman of the Audit & Risk Committee. He is Chairman of the Supervisory Board of VanLanschot Bankiers, a member of the board of directors of Zurich Financial Services and a Non-Executive Member of KPMG Europe LLP's Public Interest Committee. Tom is also Vice Chairman of the Supervisory Board and Chairman of the Audit Committee of Royal Ahold and a member of the Supervisory Board of Royal DSM. He was previously a member of the Managing Board and Chief Financial Officer of ABN AMRO.Tom is Chairman of the Supervisory Board of Van Lanschot Bankiers and Chairman of the Board of Directors of Zurich Insurance Group. He is also a member of the Supervisory Board of Royal DSM,and a Senior Adviser to Ondra Partners.The Board has determined that Tom has recent and relevant financial experience, and agreed that he has the appropriate qualifications and background to be an audit committee financial expert. |
| Mr كريسبين ديفز
| -- |
| Mr Christopher Gent
| Mr Christopher Gent is Chairman of GlaxoSmithKline PLC. Mr. Christopher Gent, appointed to the Board on 1 June 2004 and as Chairman on 1 January 2005. Sir Christopher has many years' experience of leading global businesses and a track record of delivering outstanding performance in highly competitive industries. He was appointed Managing Director of Vodafone plc in 1985 and then became its Chief Executive Officer in 1997 until his retirement in 2003. Sir Christopher has many years' experience of leading global businesses and a track record of delivering outstanding performance in highly competitive industries. He was appointed Managing Director of Vodafone plc in 1985 and then became its Chief Executive Officer in 1997 until his retirement in 2003. |
